Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70014 ↗At a glance
Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, 2025. Written by Erin R Bonner and 3 co-authors. Institution: AMYRA Biotech AG, Basel, Switzerland. Major MEDLINE topics: Glutens, Celiac Disease, Exopeptidases, Enzyme Therapy. Cited 12 times so far (Crossref); 118 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Dietary peptides are increasingly linked to inflammatory gastrointestinal diseases, exemplified by coeliac disease. Coeliac disease is caused by an acquired immune response to proline‐ and glutamine‐rich gluten peptides, which bottleneck proteolysis and provide substrates for immune recognition. Enzyme therapies aim to eliminate gluten immunogenic peptides as an adjunct to gluten‐free diet.
Aims
To investigate overlooked aspects of enzyme development given difficulties in translating preclinical efficacy into clinical benefit.
Methods
We assessed mode‐of‐action, target organ and drug delivery in the context of digestive physiology and motility for gluten‐digesting enzymes on the market or in development until 1 December 2024.
Results
Most enzymes were gastric endopeptidases specific for proline or glutamine residues. Gastric enzymes may achieve poor enzyme–substrate exposure due to limited mixing and rapid emptying of water‐soluble particles. Moreover, endopeptidases cleave proteins/peptides into shorter peptides but do not systematically cleave protein into absorbable fractions. Natural digestive physiology provides thorough mixing at the intestinal brush border, which produces exopeptidases necessary to fully digest proline‐rich peptides. Despite reduced activity in patients with coeliac disease, exopeptidases remain underexplored as therapeutic agents. Given limited substrate scope and end‐to‐end digestion, exopeptidases are ineffective as single agents, requiring functional combinations. Furthermore, vulnerability to gastric acid requires stabilisation or formulation for rapid enteric release.
Conclusions
Enzymes should be stabilised throughout the gastrointestinal tract including the small intestine. Exopeptidases perform a critical function by systematically generating absorbable fractions, warranting future investigation as therapeutic agents. Sensitive and translational biomarkers are needed to better assess enzyme efficacy in real‐meal conditions.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- AMYRA Biotech AG, Basel, Switzerland.
- Mackay Base Hospital, Mackay, Queensland, Australia.
ORCID profiles: Robert Anderson
Cite
APA
Bonner, E. R., Tschollar, W., Anderson, R., & Mourabit, S. (2025). Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70014
Vancouver
Bonner ER, Tschollar W, Anderson R, Mourabit S. Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70014
BibTeX
@article{Bonner2025,
author = {Bonner, Erin R and Tschollar, Werner and Anderson, Robert and Mourabit, Sulayman},
title = {Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70014}
}
EUVIMED